6:12 PM
 | 
Dec 10, 2012
 |  BC Extra  |  Company News

Roche submits application in EU for subcutaneous rituximab

Halozyme Therapeutics Inc. (NASDAQ:HALO) said Roche (SIX:ROG; OTCQX:RHHBY) submitted a regulatory application to EMA for a subcutaneous formulation of MabThera rituximab. The submission triggered a $4 million milestone payment...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >